熱門資訊> 正文
Ocular Therapeutix股票发行价为4.75亿美元
2025-09-30 19:19
- Ocular Therapeutix (NASDAQ:OCUL) has priced an offering of 37.9M shares at $12.53 each, aiming to raise gross proceeds of around $475.0 million.
- The offering is expected to close on or about October 1, 2025.
- The company expects to use the net proceeds from the sale, together with existing cash, to fund its planned open-label extension study for AXPAXLI in patients with wet age-related macular degeneration (wet AMD); to fund its planned Phase 3 clinical trials of AXPAXLI for the treatment of non-proliferative diabetic retinopathy; for investments in infrastructure, including capital expenditures to support manufacturing; for pre-commercialization activities associated with AXPAXLI, if approved; and for working capital and other general corporate purposes.
- OCUL +4.5% premarket to $13.1
- Source: Press Release
More on Ocular Therapeutix
- Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care
- Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript
- Key deals this week: Ocular Therapeutix, CoreWeave, Air Lease, Cadence and more
- Ocular Therapeutix gains amid takeover speculation (update)
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
